Clinical characteristics and reasons of different duration from onset to release from quarantine for patients with COVID-19 Outside Hubei province, China.

Suochen Tian; Zhenqin Chang; Yunxia Wang; Min Wu; Wenming Zhang; Guijie Zhou; Xiuli Zou; Hui Tian; Tingfang Xiao; Junmin Xing; Juan Chen; Jian Han; Kang Ning; Tiejun Wu

The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.03. 21.20038778 doi: medRxiv preprint were routinely given antiviral drugs, and two-thirds were given two antiviral drugs and one-third were given three antiviral drugs. The effects of thymosin, glucocorticoid, albumin, and immunoglobulin on COVID-19 need to be further investigated, especially in mild and moderate patients. Many studies had demonstrated the important role of TCM in inhibiting coronavirus. [20, 21, 22] Although the patients in this study were mainly mild and moderate, there was still a significant difference in the duration from onset to release form quarantine. The most important basis for release from quarantine is the persistence of negative nucleic acid test results, so the duration from onset to release form quarantine reflects the time it takes the patient to release the virus from the respiratory tract. The average time from onset to release form quarantine was 20 days. Since the patient could only be released from quarantine after three consecutive negative nucleic acid test results, and each test interval was 24 hours, and the incubation period reported in previous literature was considered [1] , the average duration of virus release in this study should be similar to that of professor Cao Bin's study . [23] Some items in the ≤ 20-day group and the > 20-day group were significantly different, which may be the reason why the quarantine cannot be released for a long time. The age of the > 20-day group was older and the time from onset to admission was later, suggesting that All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.